ICAD - Icad Inc Stock Price, Fair Value and News

1.75USD-0.02 (-1.13%)Delayed

Market Summary

USD1.75-0.02

Delayed

-1.13%

ICAD Stock Price

View Fullscreen

ICAD RSI Chart

ICAD Valuation

Market Cap

46.4M

Price/Earnings (Trailing)

-20.27

Price/Sales (Trailing)

2.57

EV/EBITDA

-6.2

Price/Free Cashflow

-8.41

ICAD Price/Sales (Trailing)

ICAD Profitability

EBT Margin

-24.82%

Return on Equity

-7.06%

Return on Assets

-5.67%

Free Cashflow Yield

-11.89%

ICAD Fundamentals

ICAD Revenue

Revenue (TTM)

18.1M

Rev. Growth (Yr)

-14.26%

Rev. Growth (Qtr)

56.23%

ICAD Earnings

Earnings (TTM)

-2.3M

Earnings Growth (Yr)

67.65%

Earnings Growth (Qtr)

-159.46%

Breaking Down ICAD Revenue

Last 7 days

15.9%

Last 30 days

12.2%

Last 90 days

20.7%

Trailing 12 Months

40.6%

How does ICAD drawdown profile look like?

ICAD Financial Health

Current Ratio

4.71

ICAD Investor Care

Shares Dilution (1Y)

4.30%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	18.1M	0	0	0
2023	20.2M	18.5M	18.2M	18.9M
2022	32.5M	32.3M	27.3M	21.9M
2021	31.8M	34.0M	36.3M	33.6M
2020	31.1M	29.4M	28.6M	29.7M
2019	26.1M	27.2M	28.9M	31.3M
2018	27.6M	27.4M	26.6M	25.6M
2017	27.1M	26.1M	27.1M	28.1M
2016	34.4M	30.6M	27.0M	26.3M
2015	48.6M	50.1M	47.1M	41.6M
2014	33.7M	35.6M	39.9M	43.9M
2013	29.9M	31.6M	31.8M	33.1M
2012	27.7M	26.9M	27.1M	28.3M
2011	25.4M	25.9M	28.4M	28.7M
2010	0	26.9M	25.8M	24.6M
2009	0	0	0	28.1M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Icad Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 31, 2023	brown dana r	bought	52,000	1.3	40,000	see remarks
Sep 12, 2022	go jonathan	sold	-106,653	2.73751	-38,960	chief technology officer
Sep 12, 2022	go jonathan	acquired	102,150	2.27	45,000	chief technology officer
Mar 03, 2022	irish timothy norris	bought	25,465	4.63	5,500	-
Feb 08, 2022	sassine andy	sold	-54,900	5.49	-10,000	-
Feb 07, 2022	sassine andy	sold	-52,600	5.26	-10,000	-
Jan 31, 2022	go jonathan	acquired	58,000	2.9	20,000	chief technology officer
Jan 07, 2022	sassine andy	sold	-60,700	6.07	-10,000	-
Jan 06, 2022	sassine andy	sold	-62,000	6.2	-10,000	-
Jan 05, 2022	stevens stacey m	bought	104,927	6.17	17,006	president

Which funds bought or sold ICAD recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	Portolan Capital Management, LLC	reduced	-1.96	-236,120	1,945,310	0.15%
May 15, 2024	DEUTSCHE BANK AG\	sold off	-100	-307,603	-	-%
May 15, 2024	STATE STREET CORP	unchanged	-	-11,542	116,137	-%
May 15, 2024	MORGAN STANLEY	reduced	-32.1	-57,420	92,736	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	sold off	-100	-28.00	-	-%
May 15, 2024	Steward Partners Investment Advisory, LLC	unchanged	-	-16.00	161	-%
May 15, 2024	Schonfeld Strategic Advisors LLC	reduced	-7.77	-13,942	72,611	-%
May 15, 2024	Squarepoint Ops LLC	added	57.59	46,738	154,565	-%
May 15, 2024	Tower Research Capital LLC (TRC)	added	1,471	4,706	5,060	-%
May 15, 2024	CAPTRUST FINANCIAL ADVISORS	added	25.83	6,538	51,762	-%

Are Funds Buying or Selling ICAD?

Are funds buying ICAD calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ICAD

No. of Funds

Unveiling Icad Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	granahan investment management, llc	1.62%	426,409	SC 13G/A
Jul 24, 2023	granahan investment management, llc	5.94%	1,510,981	SC 13G/A
Mar 15, 2023	pura vida investments, llc	5.02%	1,277,214	SC 13G
Feb 14, 2023	granahan investment management, llc	11.20%	2,849,124	SC 13G/A
Dec 09, 2022	hirschman orin	2.1%	531,981	SC 13G/A
Nov 02, 2022	granahan investment management, llc	10.2%	2,578,670	SC 13G/A
Jul 08, 2022	blackrock inc.	1.5%	371,417	SC 13G
Jul 06, 2022	hirschman orin	5.6%	1,404,898	SC 13G
Feb 14, 2022	granahan investment management, llc	9.49%	2,382,896	SC 13G
Feb 11, 2022	portolan capital management, llc	0%	0	SC 13G/A

Recent SEC filings of Icad Inc

View All Filings

Date Filed	Form Type	Document
May 15, 2024	8-K	Current Report
May 15, 2024	10-Q	Quarterly Report
Apr 29, 2024	DEF 14A	DEF 14A
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading
Mar 29, 2024	10-K	Annual Report
Mar 12, 2024	8-K	Current Report

Peers (Alternatives to Icad Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	181.0B	40.3B	-1.75%	-4.07%	32.18	4.49	-2.84%	-3.08%
BDX	68.3B	19.7B	1.78%	-6.05%	51.24	3.46	4.82%	-17.56%
ALGN	20.4B	3.9B	-9.57%	-7.50%	44.2	5.22	5.72%	46.72%
BAX	18.0B	14.9B	-10.73%	-18.01%	6.79	1.21	2.98%	207.68%
MID-CAP
ATR	9.8B	3.5B	6.68%	24.08%	31.27	2.76	6.16%	35.06%
HSIC	9.6B	12.5B	6.31%	-2.51%	24.63	0.77	-0.61%	-18.83%
BIO	8.4B	2.6B	1.13%	-22.65%	-26.02	3.22	-6.25%	-68.62%
XRAY	5.9B	3.9B	-6.79%	-30.12%	-62.84	1.49	0.23%	91.03%
AXNX	3.4B	387.1M	0.52%	31.17%	-216.3	8.9	30.82%	65.57%
PDCO	2.3B	6.6B	0.19%	-5.50%	11.93	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	5.94%	-10.00%	-1.91	0.41	7.94%	-1661.78%
ANIK	376.6M	169.3M	-1.13%	-2.23%	-4.9	2.23	7.49%	-244.90%
ANGO	241.9M	324.0M	-4.58%	-37.15%	-1.26	0.75	-3.19%	-337.41%
APYX	56.1M	50.5M	22.73%	-73.49%	-2.46	1.11	14.25%	-10.06%
AEMD	1.0M	3.7M	-71.13%	32.26%	-0.09	0.28	5.77%	8.23%

Icad Inc News

Latest updates

Icad Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	56.2%	4,954,000	3,171,000	4,073,000	5,865,000	5,778,000	2,490,000	4,359,000	7,575,000	7,523,000	7,807,500	9,361,000	7,826,000	8,644,000	10,451,000	7,129,000	5,567,000	6,551,000	9,381,000	7,857,000	7,329,000	6,773,000
Gross Profit	15.7%	4,113,000	3,553,500	3,521,000	4,349,000	4,130,000	3,107,000	3,704,000	5,491,000	5,312,000	5,704,000	6,712,000	5,538,000	6,289,000	7,462,000	5,025,000	4,357,000	4,510,000	7,165,000	6,054,000	5,726,000	5,282,000
Operating Expenses	31.5%	5,554,000	4,223,000	4,740,000	6,272,000	8,055,000	4,594,000	6,869,000	8,605,000	8,834,000	9,851,500	8,893,000	8,409,000	7,822,000	8,957,000	6,714,000	6,668,000	8,403,000	9,110,000	8,014,000	7,184,000	6,316,000
S&GA Expenses	25.2%	2,082,000	1,663,000	1,495,000	2,112,000	2,857,000	1,806,500	2,761,000	3,435,000	3,565,000	4,396,000	3,886,000	3,429,000	3,424,000	4,094,000	2,979,000	2,631,000	3,608,000	4,353,000	3,588,000	3,120,000	2,573,000
R&D Expenses	75.0%	1,507,000	861,000	1,147,000	1,263,000	2,281,000	289,000	1,407,000	2,367,000	2,275,000	2,449,000	2,285,000	2,268,000	2,192,000	2,176,000	1,849,000	1,878,000	2,211,000	2,520,000	2,485,000	2,139,000	2,127,000
EBITDA Margin	35.0%	-0.23	-0.36	-0.42	-0.53	-0.55	-0.50	-0.50	-0.39	-0.40	-0.32	-0.23	-0.23	-0.21	-	-	-	-	-	-	-	-
Interest Expenses	-100.0%	-	15,000	-	-	-	-1,500	7,000	-	9,000	-	-	29,000	112,000	116,000	115,000	115,000	130,000	180,000	193,000	202,000	209,000
Income Taxes	-42.9%	4,000	7,000	4,000	4,000	5,000	-116,500	-	-	1,000	1,000	-	-	-	4,000	3,000	5,000	26,000	10,000	6,000	19,000	8,000
Earnings Before Taxes	-150.1%	-1,218,000	-487,000	-1,033,000	-1,746,000	-3,773,000	-1,359,500	-3,103,000	-3,118,000	-3,544,000	-4,145,000	-2,176,000	-3,280,000	-1,643,000	-1,599,000	-1,794,000	-2,393,000	-11,786,000	-3,338,000	-2,950,000	-3,511,000	-3,709,000
EBT Margin	33.4%	-0.25	-0.37	-0.43	-0.54	-0.56	-0.51	-0.51	-0.40	-0.40	-0.33	-0.24	-0.24	-0.23	-	-	-	-	-	-	-	-
Net Income	-159.5%	-1,222,000	2,055,000	-1,374,000	-1,750,000	-3,778,000	-3,095,000	-3,898,000	-3,118,000	-3,545,000	-4,146,000	-2,176,000	-3,280,000	-1,643,000	-1,603,000	-1,797,000	-2,398,000	-11,812,000	-3,348,000	-2,956,000	-3,530,000	-3,717,000
Net Income Margin	50.6%	-0.13	-0.26	-0.55	-0.68	-0.69	-0.62	-0.54	-0.40	-0.40	-0.33	-0.24	-0.24	-0.23	-	-	-	-	-	-	-	-
Free Cashflow	31.8%	-1,286,000	-1,886,000	-1,760,000	-590,000	-1,650,000	-3,299,000	-2,751,000	-2,664,000	-4,600,000	-1,684,000	-2,374,000	-2,088,000	-3,825,000	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-2.5%	40.00	41.00	46.00	45.00	48.00	52.00	55.00	58.00	59.00	62.00	66.00	67.00	75.00	56.00	48.00	48.00	38.00	42.00	42.00	41.00	33.00
Current Assets	-2.1%	29.00	30.00	32.00	31.00	34.00	38.00	42.00	45.00	48.00	50.00	53.00	54.00	62.00	42.00	36.00	36.00	25.00	29.00	29.00	30.00	22.00
Cash Equivalents	-6.4%	20.00	22.00	19.00	19.00	20.00	21.00	25.00	27.00	30.00	34.00	36.00	38.00	47.00	27.00	23.00	24.00	14.00	15.00	17.00	20.00	11.00
Inventory	-18.2%	1.00	1.00	1.00	4.00	5.00	2.00	6.00	5.00	5.00	4.00	3.00	3.00	2.00	3.00	3.00	3.00	2.00	3.00	2.00	2.00	2.00
Net PPE	6.3%	2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Goodwill	0%	8.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00
Liabilities	-0.8%	8.00	8.00	15.00	15.00	16.00	17.00	18.00	17.00	15.00	16.00	16.00	16.00	22.00	25.00	22.00	21.00	23.00	37.00	33.00	30.00	29.00
Current Liabilities	-8.7%	6.00	7.00	11.00	12.00	13.00	13.00	15.00	14.00	14.00	15.00	15.00	14.00	14.00	17.00	14.00	13.00	14.00	19.00	17.00	15.00	15.00
Shareholder's Equity	-2.9%	32.00	33.00	31.00	30.00	32.00	35.00	38.00	41.00	44.00	47.00	50.00	51.00	53.00	31.00	25.00	26.00	15.00	5.00	8.00	11.00	5.00
Retained Earnings	-0.4%	-272	-271	-273	-272	-270	-266	-263	-259	-256	-253	-249	-246	-243	-241	-240	-238	-236	-224	-220	-218	-214
Additional Paid-In Capital	0.1%	307	306	306	304	303	303	303	302	302	301	300	299	298	274	267	266	252	231	230	230	220
Accumulated Depreciation	8.7%	1.00	1.00	1.00	2.00	2.00	1.00	7.00	7.00	7.00	7.00	7.00	7.00	7.00	7.00	7.00	7.00	7.00	7.00	6.00	7.00	6.00
Shares Outstanding	0.7%	27.00	26.00	26.00	25.00	25.00	25.00	25.00	25.00	25.00	25.00	25.00	24.00	24.00	-	-	-	-	-	-	-	-
Float	-	-	-	-	39.00	-	-	-	93.00	-	-	-	400,890	-	-	-	209	-	-	-	113	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	18.7%	-1,180	-1,451	-1,580	-405	-1,528	-3,130	-2,651	-2,560	-4,449	-1,547	-2,284	-2,014	-3,563	-902	-2,510	-2,157	-1,416	-2,335	-2,368	-591	-1,813
Share Based Compensation	31.2%	265	202	314	214	586	317	405	309	655	681	656	511	935	302	465	1,613	464	313	340	304	212
Cashflow From Investing	-105.2%	-206	3,950	-332	-221	-122	-169	-100	-104	-161	-137	-114	-74.00	-262	-188	-100	-30.00	-156	-87.00	-76.00	-114	-29.00
Cashflow From Financing	-100.0%	-	125	1,921	-	-	22.00	161	46.00	126	161	314	-6,930	23,546	5,643	1,018	12,156	515	308	304	8,957	972

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ICAD Income Statement

2024-03-31

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenue:
Revenue	$ 4,954,000	$ 4,334,000
Cost of revenue:
Cost of revenue	841,000	791,000
Gross profit	4,113,000	3,543,000
Operating expenses:
Engineering and product development	1,507,000	1,516,000
Marketing and sales	2,082,000	2,360,000
General and administrative	1,902,000	2,853,000
Amortization and depreciation	63,000	54,000
Total operating expenses	5,554,000	6,783,000
Loss from operations	(1,441,000)	(3,240,000)
Other income/ (expense):
Interest expense	0	0
Interest income	203,000	151,000
Other income (expense), net	20,000	3,000
Other income (expense), net	223,000	154,000
Loss before provision for income taxes	(1,218,000)	(3,086,000)
Provision for income taxes	(4,000)	(5,000)
Loss from continuing operations	(1,222,000)	(3,091,000)
Loss from discontinued operations, net of tax	0	(687,000)
Net loss and comprehensive loss	$ (1,222,000)	$ (3,778,000)
Net loss per share:
Loss from continuing operations, basic and diluted (in dollars per share)	$ (0.05)	$ (0.12)
Loss from discontinued operations, basic and diluted (in dollars per share)	0	(0.03)
Net loss per share (in dollars per share)	$ (0.05)	$ (0.15)
Weighted average number of shares used in computing loss per share:
Basic and diluted (in shares)	26,354	25,261
Product [Member]
Revenue:
Revenue	$ 3,102,000	$ 2,460,000
Cost of revenue:
Cost of revenue	480,000	425,000
Service [Member]
Revenue:
Revenue	1,852,000	1,874,000
Cost of revenue:
Cost of revenue	321,000	345,000
Amortization and Depreciation [Member]
Cost of revenue:
Cost of revenue	$ 40,000	$ 21,000

ICAD Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 20,284	$ 21,670
Trade accounts receivable, net of allowance for credit losses of $298 and $277 as of March 31, 2024 and December 31, 2023, respectively	6,515	6,392
Inventory, net	750	917
Prepaid expenses and other current assets	1,495	699
Total current assets	29,044	29,678
Property and equipment, net of accumulated depreciation of $1,136 and $1,045 as of March 31, 2024 and December 31, 2023, respectively	1,938	1,823
Operating lease assets	522	461
Other assets	299	849
Intangible assets, net of accumulated amortization of $8,500 and $8,488 as of March 31, 2024 and December 31, 2023, respectively	136	148
Goodwill	8,362	8,362
Deferred tax assets	94	97
Total assets	40,395	41,418
Current liabilities:
Accounts payable	635	712
Accrued and other expenses	1,755	2,448
Less: current portion of lease liabilities	216	188
Deferred revenue—current portion	3,554	3,400
Total current liabilities	6,160	6,748
Long-term lease liabilities	306	273
Deferred revenue, net of current	1,462	974
Deferred tax	7	6
Total liabilities	7,935	8,001
Commitments and Contingencies (Notes 9 and 12)
Stockholders’ equity:
Preferred stock, $0.01 par value: authorized 1,000,000 shares; none issued.	0	0
Common stock, $0.01 par value: authorized 60,000,000 shares; issued 26,540,030 as of both March 31, 2024 and December 31, 2023, respectively; outstanding 26,354,199 as of both March 31, 2024 and December 31, 2023, respectively.	265	265
Additional paid-in capital	306,515	306,250
Accumulated deficit	(272,905)	(271,683)
Treasury stock at cost, 185,831 shares as of both March 31, 2024 and December 31, 2023	(1,415)	(1,415)
Total stockholders’ equity	32,460	33,417
Total liabilities and stockholders’ equity	$ 40,395	$ 41,418

About Icad Inc

iCAD, Inc. engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Cancer Detection and Cancer Therapy. The company's breast AI suite includes cancer detection, automated density assessment, and breast cancer risk assessment solutions for both 2D and 3D mammography. It offers PowerLook, a back-end architecture platform, which hosts the AI algorithm solutions and manages the communications between imaging acquisition systems, and image storage and review systems; SecondLook, a machine learning-based cancer detection algorithm that analyzes 2D full-field digital mammography images to identify and mark suspicious masses and calcifications; and PowerLook Density Assessment provides automated, consistent, and standardized breast density assessments. The company also offers ProFound AI, a deep-learning algorithm designed to detect malignant soft-tissue densities and calcifications in digital breast tomosynthesis; ProFound AI Risk, a clinical decision support tool that provides breast cancer risk estimation based on a screening mammogram; and VeraLook, a solution designed to support detection of colonic polyps in conjunction with Computed Tomography Colonography. In addition, it offers Xoft Axxent electronic brachytherapy systems for the treatment of early-stage breast, non-melanoma skin, and gynecological cancers to university research and community hospitals, cancer care clinics, veterinary facilities, and dermatology offices. The company sells its products through direct sales organizations, as well as through various original equipment manufacturer partners, distributors, technology platform partners, and resellers. It also exports its products in Europe, Taiwan, Canada, China, and internationally. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was incorporated in 1984 and is headquartered in Nashua, New Hampshire.

CEO	Ms. Dana R. Brown
WEBSITE	icadmed.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	108

Icad Inc Frequently Asked Questions

What is the ticker symbol for Icad Inc? What does ICAD stand for in stocks?

ICAD is the stock ticker symbol of Icad Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Icad Inc (ICAD)?

As of Fri May 17 2024, market cap of Icad Inc is 46.45 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ICAD stock?

You can check ICAD's fair value in chart for subscribers.

What is the fair value of ICAD stock?

You can check ICAD's fair value in chart for subscribers. The fair value of Icad Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Icad Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ICAD so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Icad Inc a good stock to buy?

The fair value guage provides a quick view whether ICAD is over valued or under valued. Whether Icad Inc is cheap or expensive depends on the assumptions which impact Icad Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ICAD.

What is Icad Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, ICAD's PE ratio (Price to Earnings) is -20.27 and Price to Sales (PS) ratio is 2.57. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ICAD PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Icad Inc's stock?

In the past 10 years, Icad Inc has provided -0.132 (multiply by 100 for percentage) rate of return.